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The right organ for the right recipient: the
Ninth Annual American Society of
Transplant Surgeons State-of-the-Art
Winter Symposium
Organ transplant outcomes have improved over
the past several decades. Over this same time
period, the number of individuals with end-stage
organ failure who are potential transplant candi-
dates has rapidly increased. This increased demand
has been augmented by the expansion of recipient
selection criteria, particularly with respect to age
and other medical comorbidities. The resulting
increase in disparity between the numbers of
candidates and the supply of donors has led to
the desire to utilize organs from as many reason-
able organ donors as possible, including the use of
organs from marginal donors. As the boundaries
of both donor and recipient selection have
expanded, we are learning that outcomes are being
more heavily inﬂuenced by particular recipient and
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Abstract: With an increasing number of individuals with end-stage organ
disease and the increasing success of organ transplantation, the demand for
transplants has steadily increased. This growth has led to a greater need to
utilize organs from as many donors as possible. As selection criteria have
become less stringent to accommodate increasing demand, transplant out-
comes are more strongly inﬂuenced by recipient and donor factors; thus,
ﬁnding the right organ for the right recipient is more important than ever.
The Ninth Annual American Society of Transplant Surgeons (ASTS)
State-of-the-Art Winter Symposium, entitled ‘‘The Right Organ for the
Right Recipient,’’ addressed the matching of donor organs to appropriate
recipients. Representative dilemmas in the matching of donor organs with
recipients were discussed. These included the following: matching by donor
and recipient risk characteristics; use of organs with risk for disease trans-
mission; biologic incompatibility; use of organs from donors after cardiac
death; the justiﬁcation for combined organ transplants like liver-kidney and
kidney-pancreas; and the role of allocation in facilitating the matching of
donors and recipients. Regardless of the particular issue, decisions about
donor–recipient matching should be evidence-based, practical, and made
with the goal of maximizing organ utilization while still protecting
individual patient interests.
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donor characteristics and that certain types of
organs may be more suitable for certain types
of recipients. The Ninth Annual American Society
of Transplant Surgeons (ASTS) State-of-the-Art
Winter Symposium, entitled ‘‘The Right Organ for
the Right Recipient,’’ addressed the matching of
donor organs to appropriate recipients.
A variety of topics were addressed that reﬂect
current issues in the assignment of donor organs
and recipients. These includes the following:
matching by donor and recipient risk characteris-
tics; use of organs with risk for disease transmis-
sion; biologic incompatibility; the use of organs
from donors after cardiac death (DCD); the
justiﬁcation for the use of combined organs like
liver-kidney and kidney-pancreas; and the role of
allocation in facilitating donor–recipient matching.
Historical perspectives
William Pfaﬀ, a former president of the South-
eastern Regional Organ Procurement Foundation
(SEOPF) and the United Network for Organ
Sharing (UNOS), described the early days of organ
allocation in the lecture, ‘‘Youthful Indiscretions:
Initial Attempts to Match Donors and Recipi-
ents.’’ Organ sharing dates back to 1969 with the
original eight members of SEOPF. The early
directors were heads of transplant programs, most
of whom were surgeons. Later, membership would
include Organ Procurement Organizations (OPOs)
and histocompatibility laboratories that served
multiple programs. Decisions were largely by
consensus, and participation in sharing was volun-
tary. While sharing was very haphazard in the
1970s, as database capabilities and membership
increased, sharing became a mandatory condition
of membership - this was not welcomed by all
OPOs at the time.
The scientiﬁc reports generated as a result of
increased database capabilities were an important
part of the growth of transplantation in the early to
mid-1980s. Some of the early observations formed
the basis for allocation for many years: variation in
OPO and center outcomes, the modest eﬀect of
matching, the positive eﬀect of sharing highly
matched transplants, and the eﬀect of cold ische-
mia times (CITs). SEOPF also introduced quality
indicators in histocompatibility laboratories. In
1984, following the enactment of the National
Organ Transplantation Act (NOTA), SEOPF, as
UNOS, applied for and received the federal con-
tract for the Organ Procurement and Transplan-
tation Network (OPTN). In retrospect, as Dr. Pfaﬀ
stated, ‘‘We were only partly literate, the languages
of histocompatibility and transplant immunology
were incompletely formed. Newborn, we were
naı¨ve, but learned collectively and separately by
trial and error. I think we made reasonable rules as
went along and as new tools and actions were
contemplated. Our success was the consequence of
altruistic collaboration.’’
Donors with high risk for disease transmission
With any organ transplant, the risk of transmission
of infections or malignancy is well recognized.
There are many deleterious eﬀects if certain
diseases in the organ donor are transmitted to an
immunosuppressed transplant recipient. The
OPTN has screening policies that require all
donors to undergo serologic testing for common
diseases and diseases at high risk of transmission.
The well-known infections are syphilis and the
viral diseases cytomegalovirus, Epstein-Barr virus,
hepatitis C, hepatitis B, the human immunodeﬁ-
ciency virus (HIV), and human T-lymphotropic
viruses 1 and 2. Other viral diseases such as West
Nile, lymphocytic choriomeningits, and rabies
have been transmitted by organ transplantation,
so an accurate history and clinical acumen are
important in minimizing risk. Recipients are also at
risk for transmission of donor fungal infections
such as coccidiomycosis or histoplasmosis. Myco-
bacterium tuberculosis and parasites including
toxoplasma gondi and Chagas (Trypansoma cruzi)
have been transmitted.
While extensive donor screening processes have
been developed, the potential for the transmission
still exists. Most of the data obtained regarding the
medical and social history of donors come from
next of kin, which may be suspect in its accuracy
and completeness. The availability of screening
tests varies around the country. Screening methods
and procedures, while highly accurate, are not
perfect. False positive tests may lead to discarding
organs safe for transplants, and false negative or
absent testing of very rare diseases may result in
disease transmission. In the case of a deceased
donor, especially for either unstable donors or for
organs unable to tolerate cold ischemia, time
constraints may dictate that a decision to trans-
plant be made without complete screening infor-
mation. When testing a living donor, more time is
available, and a complete donor history and
screening can be completed.
Although the risk of disease transmission is low
in thoroughly screened donors, it is prudent that all
recipients of organs must be informed of the risk of
transmission of infection or malignancy with any
organ transplant. This information should be
shared with transplant candidates early in the
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referral process and included in educational mate-
rials. This risk discussion continues up to and
including the time of transplant.
In the Keynote debate, entitled ‘‘Tell Her About
It: Do Recipients of High-Risk Organs Require
Complete Informed Consent?,’’ the ethics of using
organs from high-risk donors and the degree to
which recipients should be informed of the risks
were discussed. ASTS President John Roberts
stated that, according to the American Medical
Association (AMA) Code of Medical Ethics in
1947, patients should hold that ‘‘obedience to the
prescriptions of his physician should be prompt
and implicit’’ and that ‘‘he should never permit
his own crude opinions as to their ﬁtness to
inﬂuence his attention to them.’’ As the medical
environment evolved to acknowledge the premise
of self-determination, the issue of the extent of
physician disclosure emerged. The Reasonable
Physician standard, by which responsibility for
disclosure’’ is limited to those disclosures which a
reasonable medical practitioner would make under
the same or similar circumstances,’’ gave way to
the Reasonable Patient Standard. By 1981, the
AMA Code of Ethics stated, ‘‘the patients right of
self-decision can be eﬀectively exercised only if the
patient possesses enough information to make an
intelligent choice.’’
In transplant situations where consent may be
required for certain types of organs (such as
expanded criteria donor kidneys or those from
high-risk donors as deﬁned by the Centers for
Disease Control [CDC]), the standard should be to
disclose what a reasonable patient would want to
know about the donor. Under this standard, what
might be considered reasonable may change with
the circumstances of the recipient (e.g., model for
end-stage liver disease (MELD) score, anticipated
time to transplant). Dr. Roberts emphasized that
informed consent is an ongoing interactive process,
especially when emotions present at the time of
oﬀer may obscure the patients decision-making
processes. He also pointed out that, contrary to
some fears, informed consent does not decrease
organ utilization (1).
Michael Abecassis, taking the opposite view,
countered that paternalism has a greater place in
decision making than is currently appreciated. The
ability to comprehend the issues and assimilate the
information required for eﬀective decision making
is extremely uncommon in patients. Patients fre-
quently follow the recommendations of their phy-
sicians, and trust in the physician plays a greater
role in patients treatment decisions compared with
other factors such as transparency, outcomes,
eﬃciency, and value. Numerous research studies
have indicated that patients typically perceive that
stated risks do not apply to them, decisions are
inﬂuenced by the way information is presented,
and very little of presented information is retained.
All of these ﬁndings suggest an important role
for an active physician role in medical decision
making.
The case of HIV transmission to organ trans-
plant recipients has raised new issues of informed
consent (2): Should potential recipients be in-
formed only about the general risks associated
with transplantation or also those speciﬁcally
associated with an identiﬁed organ? Should the
risks engendered by the behavior of donors be
treated diﬀerently from those associated with the
medical proﬁles of donors? Finally, is the supply of
transplantable organs a singular public good to be
distributed to maximize public health or is it a
market of intermittently available goods from
which eligible recipients might select to maximize
their own well-being? The concept of a standard
prospective consent for non-standard organs was
proposed. Complete disclosure would be provided
to those who ask for it, but would not be routine.
There would be exceptions for certain recipient
groups, the deﬁnition of ‘‘non-standard’’ organ
could change over time, and mechanisms to
accommodate for change in recipient status would
exist.
Crossing antibody barriers
The sensitized kidney candidate is an important
example of donor–recipient matching, as the choice
of donor can have dramatic eﬀects on the outcome
of an individual recipient. James Gloor (Mayo
Clinic) provided an overview of antibody detection
technology. Traditional assays are cell-based and
include, in increasing order of sensitivity, comple-
ment-dependent cytotoxic (CDC) crossmatch,
AHG-augmented CDC cytotoxic crossmatch, and
ﬂow cytometric crossmatch. Solid phase anti-
human leukocyte antibody (HLA) detection assays
are more sensitive than cell-based assays and
are able to quantify speciﬁc anti-HLA antibody
activity by mean ﬂuorescence intensity (MFI).
A ‘‘virtual crossmatch’’ attempts to use informa-
tion from a solid phase assay that has deﬁned
known candidate anti-HLA antibodies to predict
what would have occurred in a cell-based assay.
While standardization among laboratories has
been a concern, several studies suggest that solid
phase assays are consistent between HLA labora-
tories in identifying strong and moderate strength
antibodies, but quite variable in identifying weak
(1000–2000 MFI) antibodies. A Mayo study
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demonstrated that patients with negative ﬂow
crossmatches can have Class I or II DSA in 7%
and 20% of cases, respectively. The clinical signif-
icance of low-titer DSA detectable by solid phase
assay in the setting of a negative ﬂow crossmatch is
somewhat unclear, although some evidence exists
that those with DSA have a higher risk of
antibody-mediated rejection than those without
DSA (3).
There is a general correlation between DSA
measured by solid phase assays and channel shift
seen in ﬂow cytometric crossmatches, although on
a population level this correlation is relatively
weak. However, for a given patient, this relation-
ship is much more stable, and solid phase assays
(which do not depend on donor cells) can be very
useful in post-transplant monitoring. For a given
patient, MFI trends in post-transplant antibody
levels correlate strongly with trends in cell-based
activity as well as histologic ﬁndings on protocol
and for-cause biopsies (4).
Robert Montgomery (Johns Hopkins) then
reviewed kidney transplantation across anti-HLA
barriers. Highly sensitized patients in the United
States have extremely low rates of living or
deceased donor kidney transplantation. At Hop-
kins, two modalities are oﬀered to patients with
incompatible living donors: desensitization with
plasmapheresis and low-dose intravenous immu-
noglobulin, or kidney paired donation (KPD).
Results from desensitization at this center are
encouraging: of 187 patients who started the HLA
desensitization protocol between 1998 and 2009,
97% achieved transplantation, with a 10-yr death-
censored graft survival around 90%. Five-yr death-
censored graft survival of ABO incompatible
transplants between 1999 and 2007 was also
around 90%.
Furthermore, a striking survival advantage was
seen when comparing those who underwent
positive HLA crossmatch (+XM) kidney trans-
plantation at Johns Hopkins with matched con-
trols from the UNOS waiting list (regardless of
whether those matched controls were ultimately
transplanted).
However, there are conﬂicting pressures driving
innovation in this ﬁeld: pressures to address
vulnerable populations and take risks to achieve
transplantation vs. others to improve results and
therefore limit risk. Evidence from the Hopkins
+XM cohort suggests that risk adjustment models
may not adequately account for the risk seen in
+XM patients, and as such potentially restrict
innovation at transplant centers seeking to develop
and improve such programs. KPD oﬀers a work-
around to desensitization (5), or complements
desensitization in cases of broadly sensitized
patients who are unlikely to ever ﬁnd a negative
crossmatch (6).
Combined transplants
The use of combined transplants engenders debate
because (i) criteria for candidacy are not clearly
deﬁned, and (ii) combined transplants potentially
take a kidney from an arguably more suitable
kidney-alone candidate. David Gerber (University
of North Carolina) addressed appropriate candi-
dates for simultaneous liver and kidney (SLK)
transplantation. Comparing the pre-MELD to
MELD era there has been a 41% increase in
patients on dialysis and a 117% increase in SLK
transplants. The decision as to who requires a
combined transplant remains controversial. From
the perspective of wait list mortality, liver trans-
plant candidates on dialysis who are not listed for a
kidney have the greatest risk of death, followed by
SLK candidates on dialysis, and then SLK candi-
dates not on dialysis. Lesser degrees of renal
dysfunction correlate well with both unadjusted
candidate waitlist mortality and post-transplant
survival for liver transplant alone recipients (7).
While hepatorenal syndrome (HRS) is not usu-
ally an indication for SLK transplant, renal
recovery is unpredictable and inﬂuenced by the
presence of other perioperative conditions such as
volume status, use of vasopressors, and calcineurin
inhibitors. Pre-transplant dialysis in patients with
HRS does not appear to impact survival compared
to those with HRS who do not require dialysis.
However, HRS is associated with inferior patient
survival compared with recipients without HRS
(8). Data were presented that demonstrated that
the duration of pre-transplant creatinine elevation
is predictive of renal function six and 12 months
post-liver transplant (9).
Deceased simultaneous pancreas kidney (SPK)
vs. pancreas after living donor kidney transplant
should be viewed not as competing therapeutic
options, but rather complementary to each other
based upon patient preference, the availability of a
living kidney donor, and access to deceased donor
organs. Raja Kandaswamy from the University of
Minnesota showed that patient survival from the
time of kidney transplant for pancreas after living
donor kidney is superior to SPK transplant (99.5%
vs. 95.1% at one yr). However, pancreas survival is
greater with SPK transplant at one yr (84% vs.
78%) because of an increased risk of immunologic
graft loss for pancreas after kidney transplants.
Distinct advantages of a pancreas after living
donor kidney compared with SPK transplant
Ninth ASTS Winter Symposium Meeting Report
E595
include the inherent beneﬁt of a living donor
kidney transplant, no drain on the deceased donor
pool, decreased surgical complications, shorter
operative time, and possibly decreased waiting
time for a pancreas transplant (10). The disadvan-
tages include inferior pancreas survival compared
with a SPK, two operations with increased
expense, short-term adverse impact on renal func-
tion, and a second round of induction immuno-
suppression. In addition, organ availability may be
more limited because of local allocation rules
favoring use of SPK over solitary pancreas and
because of more stringent donor selection for
solitary pancreas compared with SPK. Given the
high mortality associated with diabetes and end-
stage renal disease, priority should be given to
obtaining a kidney for the potential recipient in as
short a time as possible. Options include the
following: living or deceased kidney transplant
alone (KTA) or SPK transplant. For those con-
sidering KTA, recipients should be made aware of
the option of pancreas after kidney transplant.
Clearly, the patients preferences in how they
prioritize their interests in kidney and pancreas
transplants are important to consider in planning
the appropriate treatment. As a general guideline,
a living donor kidney should be considered
whenever possible, especially for recipients with
long waits for deceased donor kidneys. If living
donor is not an option, an SPK transplant or
deceased donor KTA should be pursued with the
option dependent on the candidates comorbidities
and preferences, and the transplant centers waiting
time. Pancreas after kidney transplant is an
important option among patients with excellent
renal function and good health.
Donor and recipient risk/outcomes
Dorry Segev (Johns Hopkins) laid the statistical
and epidemiological groundwork for matching
donors with recipients, namely interaction or eﬀect
modiﬁcation. Traditional regression models esti-
mate the average association of one factor with
another, while adjusting for other factors that act
as confounders, so that an independent associa-
tion can be demonstrated. An example might be
that longer CIT is on average associated with
worse survival after liver transplantation, indepen-
dent of other factors that cause worse survival.
Similarly, higher donor body mass index (BMI) is
on average independently associated with worse
survival. However, among patients who receive
livers with short CIT, BMI seems to exert minimal
eﬀect, while among patients with longer CIT,
those with higher donor BMI do substantially
worse (11). Therefore, the eﬀect of BMI is
modiﬁed by CIT.
This eﬀect modiﬁcation can be studied in strat-
iﬁed models, where a diﬀerent model is used for
each stratum (category) of a suspected eﬀect
modiﬁer; or in interaction term models, where in
addition to the usual terms for the independent
eﬀects of each factor (such as one term for CIT and
one for BMI), a term is introduced for the
interaction between the factors (which would be
interpreted as the change in the eﬀect of BMI on
survival for each unit change in CIT). The choice
of model balances statistical eﬃciency, ease of
interpretation of the coeﬃcients, and underlying
assumptions of the models. Regardless of method-
ology used, understanding eﬀect modiﬁcation can
help in selecting the right donors for a given
recipients proﬁle or in selecting the right target
recipient group for a given donor (12).
Goran Klintmalm and Robert Merion debated
the value of registry predictors and statistics
compared with surgical judgment in donor–recipient
matching. Dr. Klintmalm presented the limitations
of registry data, which include the presence of
incomplete and inaccurate data entry, inability to
capture all relevant variables, and that many
patients do not ﬁt into artiﬁcially deﬁned catego-
ries. The current MELD liver allocation system
was oﬀered as an example: as the implementation
of MELD, the number of MELD exception
categories and number of cases for review has
continued to increase.
Dr. Merion argued that registry predictors, such
as those used in the donor risk index (DRI)
calculations derived for liver, kidney, and pan-
creas, are the most objective and reliable measures
to match organs and recipients. For example,
conventional surgical wisdom would suggest that
high-risk organs should be utilized in low-risk
recipients, as they would be better able to tolerate
initial graft dysfunction; however, data from the
Scientiﬁc Registry of Transplant Recipients dem-
onstrated that these patients actually fared the
worst from a transplant beneﬁt perspective (13).
Furthermore, Dr. Merion discussed the subjective
issues around deﬁning judgment, the injection of
personal bias, and the limitations of experience in
clinical decision making.
Donor and recipient matching in the high-risk
donor (as deﬁned by DRI) and DCD liver setting
was addressed by Christopher Hughes from
Emory University. Although data indicate that
ischemic cholangiopathy, primary non-function,
and graft failure are all more common among
recipients of a DCD liver, more recent data
indicate that acceptable outcomes can be achieved
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(14). Using a DCD risk index based upon ﬁve
covariates (including prior transplant in the
recipient, life support in the recipient, donor age,
donor warm ischemic time, and cold ischemic
time), it was demonstrated that organs with low-
risk scores had similar survival outcomes as
transplants from brain-dead donors (15). Addi-
tional data from the Mayo Clinic Florida that
included 108 DCD transplants revealed that DCD
recipient survival at three yr was 88.1%, compa-
rable to 81.2% among 1400 donation after brain-
death recipients. The rate of primary non-function
among the DCD organs was 4.6% and that for
ischemic cholangiopathy 7.4%. Proper donor and
recipient selection could lead to better outcomes
with the use of DCDs; however, more data are
needed to determine which recipients are at risk of
developing cholangiopathy.
Allocation
While the appropriate matching of donors and
recipients is often an issue encountered at the level
of clinical practice, such matching is also within the
purview of transplant policy. With that in mind,
Mark Stegall (Mayo Clinic) and Mitchell Henry
(Ohio State University) discussed the use of trans-
plant beneﬁt, as measured by life years from
transplant (LYFT), in kidney allocation. To
Dr. Stegall, the essential question to consider is
whether to base any allocation system on trans-
plant outcomes. Systems that would not utilize
outcomes would be either random (lottery) or
perhaps use waiting time; these are objective and
might be perceived as fair and some would be very
predictable.
Arguments in favor of outcome-based allocation
include recognition of the fact that some patients
do better than others with certain types of organs,
utility (best use of organ), stewardship of the
organ, preferences of donor families, and direction
under the Final Rule. There are many examples of
outcomes-based allocation in the current system,
including the use of listing criteria, matching,
crossmatching, and pediatric priority. While there
are other possible outcomes on which to base
allocation (graft survival, patient survival, waitlist
survival), one advantage of LYFT is that it
encompasses several of these metrics. Issues with
the use of beneﬁt-based allocation include predict-
ability, and the timeframe by which beneﬁt is
measured – short timeframes favor patients with
limited waitlist and post-transplant survival, and
longer ones favor patients with longer survival.
Regardless of the role of beneﬁt in allocation, Dr.
Stegall favors measuring it anyway, as it increases
information for patients and is a robust tool for
assessing outcomes and access to transplantation.
Dr. Henry countered that under a beneﬁt-based
system, older candidates would be disenfranchised,
as their beneﬁt tends to be lower than that of
young candidates. He admitted that adding dialysis
time (DT) and allowing candidates with less LYFT
greater access to high DRI donor organs are more
palatable. However, this still does not address the
underlying weaknesses of the model and its use
which include the following: the fact that beneﬁt
varies by timeframe (as mentioned above), there
are no identiﬁers for cardiovascular risk, and the
exclusion of race. In addition, older patients who
are sicker will get only higher risk transplants,
which will further worsen their outcomes, living
donation is likely to decrease, and LYFT score will
decrease with time on the waitlist, which will
accelerate the disparity between low and high
LYFT for access to kidneys over time. In addition,
an average increase of 0.43 yr of beneﬁt per
transplant seems meager in exchange for a less
predictable system with methodological weak-
nesses that appears to substantially shift the
demographics of recipients.
Summary
Solid organ transplant outcomes continue to
improve in an increasingly complex environment
in which recipient demand has never been higher.
As donor and recipient selection criteria have
changed to accommodate the increasing demand,
transplant outcomes are being more strongly
inﬂuenced by recipient and donor factors and that
ﬁnding the right organ for the right recipient is
more important than ever. Progress in more
eﬃcient and accurate donor screening methodol-
ogy permits transplants from organ donors with
risk factors that in the past precluded consider-
ation. More precise and speciﬁc methods for
determining and quantifying the presence of anti-
donor HLA antibody have resulted in innovative
solutions to reduce the impact of these antibody
barriers, through desensitization protocols or
working around the barriers with paired donor
exchanges. Improved data analyses of complex
dual organ recipient outcomes are improving
understanding of how to best apply combined
renal/extra-renal transplants for maximal patient
and graft survival. In addition, use of more robust
SRTR data combined with application of ad-
vanced analytical methods are helping deﬁne the
donor and recipient variables that interact and
impact clinical outcomes. This has also led to
donor risk indices for speciﬁc organs that improve
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our ability to forecast outcomes, thus allowing
improved decision making and informed consent
for prospective recipients. All of these advances
also stimulate re-evaluation of current organ allo-
cation policies.
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